medigraphic.com

2024, Number 2

<< Back Next >>

Rev Fac Med UNAM 2024; 67 (2)

Coagulation Disorders: Factor V Leiden, Biological, Clinical, and Epidemiological Overview

Hernández-Girón C, Cabrales-Arreola JL

Language: Spanish
References: 26
Page: 7-18
PDF size: 359.38 Kb.


ABSTRACT

The coagulation system always keeps the blood in a fluid state and is therefore incessantly active throughout life. However, the moment an injury to the vascular system occurs, the coagulation system immediately rotates 180° and transforms the blood into a perfectly localized solid body, which we call a clot. This process, by which a clot forms, is known as hemostasis, which is one of the components of the coagulation system.
The importance of the Leiden mutation of factor V is based on the following: coagulation factor V is a protein that is synthesized in the liver and the gene that encodes it is located in region 23 of the long arm of chromosome 1, this factor circulates in peripheral blood inactively until it interacts with activated factor X forming a complex that converts factor II (prothrombin) into thrombin, which will have its action on fibrinogen turning it into fibrin. The regulation of activated factor V is given by the activity of activated protein C, when factor V has a mutation (named Leiden) that is caused by the exchange of an adenine for a guanine in the nucleotide 1691 of factor V (G1691A), which causes arginine to be replaced by a glutamine in the 506 residue of the factor V protein, the resulting protein is an abnormal factor V, which cannot be inactivated by activated protein C, so factor V remains activated and cannot prevent the clotting process from stopping.
In our country (considering several conditions) it has been described in various publications of Mexican researchers that Leiden mutations of factor V and G20210A of prothrombin are not frequent, as they are in European countries.


REFERENCES

  1. Majluf-Cruz A, Trombofilia. Gac Med Mex. 2017;153(4):427-429. doi:10.24875/GMM.M17000013

  2. Parra-Ortega I, López-Valladares KE, Angeles-FlorianoT, Moreno-González AM, López-Martínez B. La existenciade las mutaciones Leiden del factor V y G2021Ade la protrombina es infrecuente en pacientes pediátricosmexicanos con hemofilia A grave. Rev Hematol Mex.2019;20(3):198-203.

  3. World Federation Hemophilia (WFH). [Consultado 10abril, 2022]. Disponible en: http://tinyurl.com/22yhsz2c

  4. Aguirre HD, Posada A. Deficiencia congénita del factor V.2014;28(2):247-252. Recuperado de: https://www.redalyc.org/articulo.oa?id=261132654009

  5. Gómez Baute R, Guerra Alfonso T, Dita Salabert L, FernándezÁguila JD, Cabrera Zamora M. Teoría celular de lacoagulación: de las cascadas a las membranas celulares. Medisur[Internet]. 2011 Abr [citado 2022 Nov 02];9(2):146-155. Disponible en: http://tinyurl.com/2blm3d9y

  6. Kiekebusch H Gustavo, Perucca P Ernesto. Trombofiliashereditarias. Rev. chil. obstet. ginecol. [Internet]. 2003[citado 2022 Nov 02];68(5):424-429. Disponible en: http://tinyurl.com/2bx97696. https://doi.org/fm85zs

  7. Benítez-Aranda H. Avances en el tratamiento de la hemofilia.Revista Médica del Instituto Mexicano del SeguroSocial [Internet]. 2005;43(1):S135-S138. Recuperado de:http://tinyurl.com/277or2dx

  8. López T, Delgado V, Puentes D, Araque W, Rosales A, GranadilloA, Rojas M, Bimanis Judith. Frecuencia de la mutacióndel factor V Leiden y de protrombina G20210A en pacientescon tromboembolismo venoso. Salus [Internet]. 2007;11(3):37-40. Recuperado de: http://tinyurl.com/2dllz7xx

  9. Price DT, Ridker PM. Factor V Leiden mutation and therisks for thromboembolic disease: a clinical perspective.ACP J Club. 1998 Mar-Apr;128(2):52.

  10. Rydz N, James PD. Why is my patient bleeding or bruising?Hematol Oncol Clin North Am. 2012 Apr;26(2):321-44,viii. doi: 10.1016/j.hoc.2012.01.002. PMID: 22463830.

  11. Noroña Calvachi CD. Trombofilias hereditarias. Revistacientífica ciencia médica [Internet]. 2015;18(1):43-49. Recuperadode: http://tinyurl.com/23kd45fk

  12. Liang J, Wu S, Feng B, Lei S, Luo G, Wang J, Li K, Li X,Xie H, Zhang D, Wang X, Wu K, Miao D, Fan D. Factor VLeiden and inflammatory bowel disease: a systematic reviewand meta-analysis. J Gastroenterol. 2011 Oct;46(10):1158-66. doi: 10.1007/s00535-011-0441-7. Epub 2011 Jul 30.PMID: 21805067.

  13. Papa A, De Stefano V, Gasbarrini A, Chiusolo P, CianciR, Casorelli I, Paciaroni K, Cammarota G, Leone G, GasbarriniG. Prevalence of factor V Leiden and the G20210Aprothrombin-gene mutation in inflammatory bowel disease.Blood Coagul Fibrinolysis. 2000 Jul;11(5):499-503.https://doi.org/bhkn65. PMID: 10937811.

  14. Juliao Baños F. Calidad en el manejo de enfermedad inflamatoriaintestinal. Rev col Gastroenterol [internet]. 2011sep [citado 30 ago 2022];26(3):211-220. Consultado: http://tinyurl.com/28zsz6zg

  15. Maessen Visch MB, Hamulyak K, Tazelaar DJ, CrombagNH, Neumann HA, The prevalence Factor V Leiden mutationin patients with leg ulcers and venous insufficiency.Arch Dermatol. 1999 Jan;135(1):41-4. Doi: 10.1001/archderm.135.1.41.

  16. Franchini M, Montagnana M, Manzato F, Vescovi P P.Thyroid dysfunction and hemostasis: an issue still unresolved.Semin Thromb Hemost. 2009 Apr;35(3):288-94.Doi: 10.1055/s-0029-1222607.

  17. Franchini M, Lippi G, Favaloro EJ. Coagulopathies andtrombosis: usual and unusual causes and association, part I.Semin Thromb Hemost. 2009 apr;35(3)257-9 doi: 10.1055/s-0029-1222603. Epub 2009 May 18. PMID: 19452400.

  18. Majluf-Cruz A, Moreno-Hernández M, Ruiz de Chávez-Ochoa A, Monroy-García R, Majluf-Cruz K, GuardadomendozaR, Molina-Ávila I, Isordia-Salas I, Corona-de laPeña N, Vargas Vorackova- F, Vela-Ojeda J, García-ChavezJ. Activated Protein C Resistance and Factor V Leiden InMéxico. Clinical and Applied Thrombosis/Hemostasis. 2008Oct;14(4):428-437.

  19. Zavala-Hernández C, Hernández-Zamora E, Martínez-Murillo C, Arenas-Sordo ML, González Orozco AE, Reyes-Maldonado E. Asociación de la RCPA con mutacionesLeiden y Cambridge del Factor V de la coagulación enpacientes mexicanos con trombofilia primaria. Cirugía yCirujanos. 2010 Mar;78(2):131-136

  20. Reséndiz-Figueroa FE, Ortiz-Garrido OM, Pulido D, Arcila-Martínez D, Schmulson M. Impacto de los rasgos de ansiedady depresión sobre aspectos clínicos y calidad de vidaen pacientes con síndrome de intestino irritable. Revista degastroenterología de México. 2008 Ene;73(1):3-10.

  21. Palomo G Iván, Pereira G Jaime, Alarcón L Marcelo, PinochetP Carmen, Vélez SM María T, Hidalgo P Patricia et al.Factor V Leiden y mutación de la protrombina G20210A enpacientes con trombosis venosa y arterial. Rev. méd. Chile[Internet]. 2005 Dic [citado 2022 Ago 30];133(12):1425-1433. Disponible en: http://tinyurl.com/2bnbntey. https://doi.org/d5x7z8

  22. Dick-Guareschi J, Fontana J cristine, Vieira SanseverinoM Teresa, Kubaski F, Sekine L, Mesquita N Félix et al.Prevalence of thrombophilia-associated genetic risk factorsin blood donors of a regional hospital in southern Brazil,Hematology, Transfusion and Cell Therapy [Internet]. 2021https://doi.org/mjfp

  23. Rubio-Jurado B, Salazar-Páramo M, Medrano-Muñoz F,Gomnzález-Ojeda A, Nava A. Trombofilia, autoinmunidady trombofilaxis perioperatoria. Cirugía y Cirujanos [Internet].2007;75(4):313-321. Recuperado de: http://tinyurl.com/28xwt326

  24. Sandoval-Chagoya, G A, Laniado-Laborín, R. Profilaxis parala trombosis venosa profunda. Revista Médica del InstitutoMexicano del Seguro Social [Internet]. 2013;51(6):688-691.Recuperado de: http://tinyurl.com/22ayjkcg

  25. Restrepo-Ochoa O. Trombosis-trombofilia en alto riesgoobstétrico. Revista Colombiana de Obstetricia y Ginecología[Internet]. 2003;54(1):47-68. Recuperado de: http://tinyurl.com/2a34c658

  26. González González N, Benhumea-González LE, Tinoco-García AM. Salud mental y emociones en pacientes conenfermedades crónico-degenerativas. Un acercamiento ala diabetes mellitus tipo 2. Espacios Públicos [Internet].2011;14(32):258-279. Recuperado de: http://tinyurl.com/y6sbsu4j




2020     |     www.medigraphic.com